Registration is OPEN for #GlomConEurope2027 April 19–21 | Hilton Budapest Hotel. Three days of glomerular disease education and research.
Register 👉 glomcon.org/glomcon-europe
@GlomConPortugal #Nephrology #GlomerularDisease #KidneyHealth
FDA approves Gazyva® (obinutuzumab) for adult patients with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria. Based on the Phase 3 MAJESTY study.
Full PI: gene.com/download/pdf/gazyva…
#Nephrology #MembranousNephropathy
glomcon retweeted
⏰ Starting in 10 minutes!
Join our CEO @EndlichNicole at @GlomCon for “Seeing the Unseen, Measuring What Matters” — super-resolution imaging for kidney research and clinical studies.
💻 Zoom: 817 4374 4653
Passcode: 202122
#GlomCon #Nephrology
glomcon retweeted
Replying to @EndlichNicole
@EndlichNicole rocks! Fantastic talk on the role of Podocyte Exact Morphology Measurement Procedure in kidney structures analysis, finding biomarkers and novel drugs 🔬💊@NIPOKA_Podocyte @GlomCon @ISGDtweets
glomcon retweeted
A glimpse from today’s @GlomCon seminar 🔬
Our CEO @EndlichNicole on quantitative super-resolution imaging for #kidney research and clinical studies.
Thank you to @GlomCon and @d_r_waguespack for hosting us!
#Nephrology #Podocytes
glomcon retweeted
Join RPS-GlomCon for Renal Pathology Webinar Series
To register:renalpathsoc.org/event-67192…
#renalpath @glomcon
Join us this Sunday for the next GlomCon Sunday Seminar.
Seeing the Unseen: Quantitative Super-Resolution Imaging
Presented by Nicole Endlich, PhD
Sunday, Nov 15 · 8:00AM PST
Zoom ID: 81743744653 · Passcode: 202122
Register: glomcon.org
#nephrology #kidneyhealth
glomcon retweeted
I’m still thinking about our lecture with @pranavgarimella at PKD-MD program today @GlomCon. PGT can play a huge role in monogenic diseases… #Genetic #PKD #EndPKD
Fantastic lecture as always by Dr. Garimella ⭐️👌🏻
glomcon retweeted
Just published in #RKD
link.springer.com/article/10…
Even in patients with a stable eGFR (annual eGFR decline < 1 mL/min/year, over 2 years), achievement of KDIGO-recommended TA-P confers protection from kidney failure!
@GlomCon
glomcon retweeted
Fantastic session by Prof. Gerald Appel on lupus nephritis at the @GlomCon Fellowship program. We’re grateful to learn from his expertise, wisdom, and insights
Join GlomCon this Sunday for the next GlomCon Sunday Seminar.
Congenital Renal Anomalies and Cystic Kidney Diseases
Presented by Stephen M. Bonsib, MD
Sunday, November 8, 2026 8:00AM PDT
Zoom ID: 81743744653
Passcode: 202122
Register to join live: glomcon.org
#kidneydisease #kidneyhealth #nephrology #kidneyeducation #kidneyresearch
glomcon retweeted
link.springer.com/article/10…
A strong message by Bill Wang about "the rare, the common, the hope-including the excluded" - a patient perspective on rare kidney diseases, just published in #RKD - worthwhile a read, I promise!
@GlomCon
glomcon retweeted
Complete summary and more of IgA nephropathy using mass spectrometry.
1. Majority of IgA is IgA1.
2. Smaller amounts of IgA2 are also present.
3. Both IgA1 and IgA2 colocalize with IgG, showing that the deposits are composed of IgA1/IgG and IgA2/IgG.
4. Dominant IgG subclass is IgG1.
5. J chain that binds monomers of IgA into dimers is present in majority of cases, indicating that the IgA is mucosal derived (as circulating IgA is monomer and doesn’t have J chain)
6. Absence of PIGR indicates that IgA is not derived from secretions such as saliva, tears, etc. PIGR is a peptide in IgA (present in secretions), that prevent the breakdown of IgA by bacteria.
Taken together: IgA immune complexes in IgA nephropathy are made up of antigenic (galactose-deficient) mucosal-derived IgA and IgG.
7. Complement: Large amounts of C3 and C9 indicating alternative and terminal pathways of complement activation.
8. Minimal classical/no lectin pathway proteins.
9. Some correlation with MESTC score but bottom line= all IgA nephropathy shows lots of C3 and C9.
10. Abundant CFHR5 indicating that there is breakdown of C3 into inactive C3=iC3b.
11. Complement is a major player in the inflammatory process in IgA nephropathy.
kidney-international.org/art…
glomcon retweeted
Always a pleasure to see the @GlomCon family!
It’s amazing to see how much you’ve accomplished and how far GlomCon has come! ✨
#KidneyWk #kidneyweek2026 #Denver
How low is low enough? New research explores the relationship between proteinuria levels and long-term kidney survival in immunoglobulin A nephropathy (IgAN), highlighting the importance of even very low proteinuria levels.
📅 Published October 8, 2026
🔗 Read the abstract: bit.ly/4hUzRjf
#GlomCon #Nephrology #KidneyResearch #RareKidneyDiseases #IgAN
How low is low enough? New research explores the relationship between proteinuria levels and long-term kidney survival in immunoglobulin A nephropathy (IgAN), highlighting the importance of even very low proteinuria levels.
📅 Published October 8, 2026
🔗 Read the abstract: bit.ly/4hUzRjf
#GlomCon #Nephrology #KidneyResearch #RareKidneyDiseases #IgAN
glomcon retweeted
Our first Editorial Board meeting happened yesterday evening- small group, but fruitful discussions! @GlomCon Photo with @wisit661 and @poyanmehr
Running a clinical trial is one thing. Running a trials program that pays for itself is another.
The new GlomCon Trialist Training Program teaches the operational side: Budget negotiation, staffing, regulatory compliance, sponsor relations. For academic centers and private practices alike. Free for GlomCon Rare Kidney Disease Network members.
Applications open on November 23, 2026.
Learn more at glomcon.org
#ClinicalTrials #Nephrology #RareDisease #GlomCon
The Kidney Pathology Certificate Program returns for its 2027 cohort.
Twelve months, six modules, from biopsy basics to allograft pathology: Live case webinars led by renal pathologists and nephrologists, pre-recorded lectures, and a certificate upon completion of program.
Directed by Vanesa Bijol, MD and Ibrahim Batal, MD.
Applications open on October 26, 2026.
Learn more at glomcon.org
#RenalPathology #Nephrology #Nephropathology #GlomCon






































